Exelixis price target raised to $64 from $35 at H.C. Wainwright H.C. Wainwright analyst Michael King raised the firm's price target on Exelixis to $64 from $35 and keeps a Buy rating on the shares post the Q2 beat.Our Take: "This is also a Buy for us as well. This is a profitable biotech with a promising future. We would buy the stock, long leaps, and short some puts." $EXEL, Exelixis, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .